Osteopontin—An important downstream effector of S100A4‐mediated invasion and metastasis

Substantial evidence has linked the small calcium‐binding protein S100A4 to metastatic progression. S100A4‐mediated effects include stimulation of angiogenesis, regulation of cell death and increased cell motility and invasion, but the exact molecular mechanisms by which the protein exerts these effects are incompletely elucidated. In the present study, we demonstrate that S100A4 induces NF‐κB‐dependent expression and secretion of osteopontin (OPN) in a selection of osteosarcoma cell lines. OPN is, as S100A4, known to result in a variety of cellular effects potentially leading to increased angiogenesis and metastasis, and several of the activated signaling pathways are common for the two proteins. In our study, extracellular S100A4 was found to upregulate enzymes of the plasminogen activator system and matrix metalloproteinase (MMP) family, especially urokinase plasminogen activator and MMP‐13. Furthermore, increased motility and invasion was observed in vitro as a result of S100A4 treatment. OPN expression was inhibited by the use of siRNA molecules, and a partial blocking of S100A4‐induced effects on protease expression and invasive capacity was detected. In conclusion, our results suggest regulation of OPN as a downstream molecular mechanism of S100A4 signaling. This novel finding adds more information to how S100A4 mediates tumor development and metastatic progression. The observation of a link between S100A4 and OPN, and also identification of common downstream effect molecules, highlights them, their receptors or downstream proteins, as targets for therapeutic approaches.

[1]  R. Samant,et al.  Osteopontin: an effector and an effect of tumor metastasis. , 2010, Current molecular medicine.

[2]  W. Robinson,et al.  Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[3]  D. Zhang,et al.  Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells , 2009, Oncogene.

[4]  V. A. Flørenes,et al.  Different Expression and Clinical Role of S100A4 in Serous Ovarian Carcinoma at Different Anatomic Sites , 2009, Tumor Biology.

[5]  Xuchao Xue,et al.  A small interfering RNA targeting osteopontin as gastric cancer therapeutics. , 2008, Cancer letters.

[6]  Hyojin Cho,et al.  New pathway links from cancer‐progression determinants to gene expression of matrix metalloproteinases in breast cancer cells , 2008, Journal of cellular physiology.

[7]  E. Hovig,et al.  Activation of NF‐κB by extracellular S100A4: Analysis of signal transduction mechanisms and identification of target genes , 2008, International journal of cancer.

[8]  R. Weinberg,et al.  Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.

[9]  M. El-Tanani,et al.  Role of osteopontin in cellular signaling and metastatic phenotype. , 2008, Frontiers in bioscience : a journal and virtual library.

[10]  Aamir Ahmad,et al.  Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.

[11]  P. Kuo,et al.  Osteopontin: regulation in tumor metastasis , 2008, Cancer and Metastasis Reviews.

[12]  M. Duffy,et al.  Cancer invasion and metastasis: changing views , 2008, The Journal of pathology.

[13]  Dao-Qiang Zhang,et al.  The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA , 2007, Cellular & Molecular Biology Letters.

[14]  Y. De rycke,et al.  A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients , 2007, International journal of cancer.

[15]  G. Casey,et al.  Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activation , 2007, Molecular Cancer.

[16]  K. Pavelka,et al.  S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases , 2006, Annals of the rheumatic diseases.

[17]  A. Bresnick,et al.  Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. , 2006, Arthritis and rheumatism.

[18]  G. Casey,et al.  Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435 , 2006, Clinical & Experimental Metastasis.

[19]  S. Leinster,et al.  Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  David J Weber,et al.  S100A4, a Mediator of Metastasis* , 2006, Journal of Biological Chemistry.

[21]  O. Fodstad,et al.  Matrix metalloproteinases participate in osteosarcoma invasion. , 2005, The Journal of surgical research.

[22]  M. Grigorian,et al.  Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. , 2005, Cancer research.

[23]  M. Grigorian,et al.  Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity , 2004, Oncogene.

[24]  M. Grigorian,et al.  Functional Significance of Metastasis-inducing S100A4(Mts1) in Tumor-Stroma Interplay* , 2004, Journal of Biological Chemistry.

[25]  E. Hovig,et al.  S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells , 2003, Clinical & Experimental Metastasis.

[26]  G. Kundu,et al.  Osteopontin Stimulates Cell Motility and Nuclear Factor κB-mediated Secretion of Urokinase Type Plasminogen Activator through Phosphatidylinositol 3-Kinase/Akt Signaling Pathways in Breast Cancer Cells* , 2003, Journal of Biological Chemistry.

[27]  R. Donato,et al.  Intracellular and extracellular roles of S100 proteins , 2003, Microscopy research and technique.

[28]  A. Chott,et al.  Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors , 2002, Virchows Archiv.

[29]  A. Angelucci,et al.  Osteopontin Modulates Prostate Carcinoma Invasive Capacity through RGD-Dependent Upregulation of Plasminogen Activators , 2002, Biological chemistry.

[30]  S. Curran,et al.  The Structure, Regulation, and Function of Human Matrix Metalloproteinase-13 , 2002, Critical reviews in biochemistry and molecular biology.

[31]  G. Weber The metastasis gene osteopontin: a candidate target for cancer therapy. , 2001, Biochimica et biophysica acta.

[32]  A. Chambers,et al.  Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent , 2001, Breast Cancer Research and Treatment.

[33]  S. Philip,et al.  Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-κB-mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells* , 2001, The Journal of Biological Chemistry.

[34]  V. Berezin,et al.  The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor , 2001, Oncogene.

[35]  P. Choong,et al.  The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Scott,et al.  Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphorylation and self-assembly of the heavy chain of nonmuscle myosin. , 2000, Biochimica et biophysica acta.

[37]  J. Rutter,et al.  Interstitial collagenases as markers of tumor progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  P. Choong,et al.  Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases — A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases , 2000, Breast Cancer Research and Treatment.

[39]  J. Winstanley,et al.  Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. , 2000, Cancer research.

[40]  O. T. Odegaard,et al.  S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. , 1999, Cancer research.

[41]  M. C. Ling,et al.  Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells , 1999, Oncogene.

[42]  E. Hovig,et al.  Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. , 1996, Cancer research.

[43]  M. Grigorian,et al.  Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. , 1996, Oncogene.

[44]  P. Rudland,et al.  Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. , 1996, Oncogene.

[45]  C. Heizmann,et al.  Expression of Ca2+‐binding proteins of the S100 family in malignant human breast‐cancer cell lines and biopsy samples , 1994, International journal of cancer.

[46]  P. Rudland,et al.  Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. , 1993, Oncogene.

[47]  A. Minami,et al.  The role of osteopontin in tendon tissue remodeling after denervation-induced mechanical stress deprivation. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[48]  M. Crippa Urokinase-type plasminogen activator. , 2007, The international journal of biochemistry & cell biology.

[49]  C. Brinckerhoff,et al.  Matrix metalloproteinases: role in arthritis. , 2006, Frontiers in bioscience : a journal and virtual library.

[50]  M. Grigorian,et al.  Suppression of Tumor Development and Metastasis Formation in Mice Lacking the S 100 A 4 ( mts 1 ) , 2005 .

[51]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.